EGFR and non-small cell lung carcinoma: In the FLAURA study, post-hoc analysis showed that in advanced treatment naïve EGFR-mutant NSCLC patients with PD-L1≧1%, the median PFS was 18.4 months with osimertinib, and 6.9 months with gefitinib and erlotinib (HR 0.30 (95% CI, 0.15 to 0.60))24.